Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884315 | 0.79 | MAPK14 (0.57) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1883322 | 0.79 | MAPK14 (0.44) | MAPK14MAPKAPK2 | |
| SCHEMBL1878872 | 0.72 | HCAR1 (0.39) | MAPK14HDAC9 | |
| SCHEMBL1880265 | 0.71 | MAPK14 (0.73) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3668107 | 0.68 | MAPK14 (0.47) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL1882664 | 0.68 | MAPK14 (0.34) | MAPK14HDAC9 | |
| SCHEMBL4092033 | 0.66 | MAPK14 (0.55) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3767381 | 0.66 | MAPK14 (0.65) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3757488 | 0.66 | MAPK14 (0.65) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA | |
| SCHEMBL3671305 | 0.65 | MAPK14 (0.60) | MAPK14MAPKAPK2MAPK13RAF1PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367671-B2 | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents | AMGEN INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | AMGEN INC. (US) | 2011-05-05 | — | — | US | disclosed |
| WO-2009117156-A1 | PYRAZOLO-PYRAZINONE COMPOUNDS AND METHODS OF USE THEREOF | AMGEN INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105499-A1 | Pyrazolo-Pyrazinone Compounds and Methods of Use Thereof | MAPK1, MAP3K1, MAP4K2 | MAPK14 32/4885MAPKAPK2 28/4885MAPK13 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.